Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 11Osteoporosis 6Neoplasms 4Melanoma 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Cardiovascular Diseases 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Regional Osteoporosis as a Result of Chemotherapy 1Recurrence 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

vandetanib 14cabozantinib 9selpercatinib 6Sorafenib 5Everolimus 5pralsetinib 3Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Thyroidectomy 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Absorptiometry, Photon × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡